A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack

Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinical and real-world data on ROCK inhibitor"based regimens for glaucoma, comparing monotherapy and combination therapy approaches for lowering IOP. Faculty will discuss the use of ROCK inhibitors to achieve individualized patient-specific treatment goals and review a clinical case to provide additional context for applying these therapies in practice.